Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
作者： E. David Crawford , Celestia S. Higano , Neal D. Shore , Maha Hussain , Daniel P. Petrylak
DOI: 10.1016/J.JURO.2015.06.106
关键词:
摘要: Purpose: The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review efficacy safety new agents current knowledge regarding would enable treating physicians to make rational drug selections in patients cancer.Materials Methods: We searched MEDLINE® relevant congresses cabazitaxel, docetaxel, 223radium dichloride, abiraterone, enzalutamide sipuleucel-T, focusing strategies, mechanisms biomarkers response.Results: Abiraterone target the androgen axis different action. blocks cytochrome P450 17, inhibiting synthesis, whereas inhibits receptor, reducing nuclear translocation receptor complex subsequent DNA bindin...
elsevier.com
jurology.com 参考文章(50)
Sushil Badrising, Vincent van der Noort, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Paul Hamberg, Jules L. Coenen, Alfons J. M. van den Eertwegh, Igle J. de Jong, Emile D. Kerver, Harm van Tinteren, Andries M. Bergman, Clinical Activity and Tolerability of Enzalutamide (MDV3100) in Patients With Metastatic, Castration-Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment Cancer. ,vol. 120, pp. 968- 975 ,(2014) , 10.1002/CNCR.28518
Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles, Thomas W. Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia S. Higano, Mary-Ellen Taplin, Thomas W. Griffin, Mary B. Todd, Margaret K. Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) European Urology. ,vol. 66, pp. 815- 825 ,(2014) , 10.1016/J.EURURO.2014.02.056
O B Goodman, T W Flaig, A Molina, P F A Mulders, K Fizazi, H Suttmann, J Li, T Kheoh, J S de Bono, H I Scher, Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases. ,vol. 17, pp. 34- 39 ,(2014) , 10.1038/PCAN.2013.41
Eleni Efstathiou, Mark Titus, Sijin Wen, Anh Hoang, Maria Karlou, Robynne Ashe, Shi Ming Tu, Ana Aparicio, Patricia Troncoso, James Mohler, Christopher J. Logothetis, Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer European Urology. ,vol. 67, pp. 53- 60 ,(2015) , 10.1016/J.EURURO.2014.05.005
Charles J. Ryan, Arturo Molina, Jinhui Li, Thian Kheoh, Eric J. Small, Christopher M. Haqq, Russell P. Grant, Johann S. de Bono, Howard I. Scher, Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial Journal of Clinical Oncology. ,vol. 31, pp. 2791- 2798 ,(2013) , 10.1200/JCO.2012.45.4595
Praful Ravi, Joaquin Mateo, David Lorente, Zafeiris Zafeiriou, Amelia Altavilla, Roberta Ferraldeschi, Spyridon Sideris, Emily Grist, Alan Smith, Sophia Wong, Diletta Bianchini, Gerhardt Attard, Johann S. de Bono, External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone European Urology. ,vol. 66, pp. 8- 11 ,(2014) , 10.1016/J.EURURO.2014.03.020
Stephen Harland, John Staffurth, Arturo Molina, Yanni Hao, Dennis D. Gagnon, Cora N. Sternberg, David Cella, Karim Fizazi, Christopher J. Logothetis, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono, Howard I. Scher, Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy European Journal of Cancer. ,vol. 49, pp. 3648- 3657 ,(2013) , 10.1016/J.EJCA.2013.07.144
Michael S. Cookson, Bruce J. Roth, Philipp Dahm, Christine Engstrom, Stephen J. Freedland, Maha Hussain, Daniel W. Lin, William T. Lowrance, Mohammad Hassan Murad, William K. Oh, David F. Penson, Adam S. Kibel, Castration-Resistant Prostate Cancer: AUA Guideline Journal of Urology. ,vol. 190, pp. 429- 438 ,(2013) , 10.1016/J.JURO.2013.05.005
Frederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen, Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scandinavian Journal of Urology and Nephrology. ,vol. 48, pp. 268- 275 ,(2014) , 10.3109/21681805.2013.860189
Eleni Efstathiou, Mark Titus, Dimitra Tsavachidou, Vassiliki Tzelepi, Sijin Wen, Anh Hoang, Arturo Molina, Nicole Chieffo, Lisa A. Smith, Maria Karlou, Patricia Troncoso, Christopher J. Logothetis, Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone Journal of Clinical Oncology. ,vol. 30, pp. 637- 643 ,(2012) , 10.1200/JCO.2010.33.7675